Quickstart Highlights
PT-141 (bremelanotide) and Melanotan II are cyclic melanocortin receptor agonists with distinct but related applications. PT-141 is FDA-approved for hypoactive sexual desire disorder and is used on-demand, while Melanotan II has been studied for its effects on skin pigmentation and sexual function with daily dosing protocols. This educational guide covers reconstitution, dosing, and administration for both peptides.
- Separate vials: PT-141 10 mg and Melanotan II 10 mg. Use 2.4 mL BAC per vial; calculations assume a final 2.4 mL in each separate vial (4.1667 mg/mL nominal). This is not a combined-vial blend.
- PT-141 dose: 750–1750 mcg on-demand (≥45 min before activity); max 1 dose per 24 h.
- Melanotan II dose: 250–1000 mcg once daily with gradual titration.
- Scale conversion: 1 unit = 0.01 mL ≈ 41.667 mcg of the peptide in that separate vial.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~1 week.
Dosing & Reconstitution Guide
PT-141: volume and device references (2.4 mL)
Route: Subcutaneous injection (abdomen or thigh). Frequency: On-demand, at least 45 minutes before anticipated sexual activity; no more than 1 dose per 24 hours and ≤8 doses per month.
| Phase | Dose (mcg) | Calculated volume | 1 mL U-100 syringe | V1 setting (units) |
|---|---|---|---|---|
| Initial / Titration | 500–750 mcg | 0.12–0.18 mL (endpoints) | 12–18 units (endpoints) | 12 or 18 units; check each intermediate amount |
| Standard | 1000–1500 mcg | 0.24–0.36 mL (endpoints) | 24–36 units (endpoints) | 24 or 36 units; check each intermediate amount |
| 1.75 mg reference | 1750 mcg (1.75 mg) | 0.42 mL | 42 units | 42 units |
Calculation basis: Labelled 10 mg in an assumed final 2.4 mL (4.16667 mg/mL). These nominal conversions do not validate preparation, compatibility or a treatment schedule.
U-100 syringe: 100 units = 1 mL. Check the markings on your syringe before measuring.
V1 pen: Adjusts in 1-unit steps, from 1 to 80 units per setting. Cartridge capacity: 3 mL. Delivery accuracy is not independently validated here.
Titration: Start at a lower dose (500–750 mcg) and increase as tolerated. Nausea is common with initial use and typically diminishes with subsequent doses.
Melanotan II: volume and device references (2.4 mL)
Route: Subcutaneous injection (abdomen or thigh). Frequency: Once daily during loading phase; reduced frequency for maintenance.
| Week | Daily Dose (mcg) | Calculated volume | 1 mL U-100 syringe | V1 setting (units) |
|---|---|---|---|---|
| Week 1 | 250 mcg | 0.06 mL | 6 units | 6 units |
| Week 2 | 500 mcg | 0.12 mL | 12 units | 12 units |
| Weeks 3–4 | 750 mcg | 0.18 mL | 18 units | 18 units |
| Weeks 5+ (Loading) | 1000 mcg | 0.24 mL | 24 units | 24 units |
| Maintenance | 500–1000 mcg (2–3×/week) | 0.12–0.24 mL (endpoints) | 12–24 units (endpoints) | 12 or 24 units; check each intermediate amount |
Calculation basis: Labelled 10 mg in an assumed final 2.4 mL (4.16667 mg/mL). These nominal conversions do not validate preparation, compatibility or a treatment schedule.
U-100 syringe: 100 units = 1 mL. Check the markings on your syringe before measuring.
V1 pen: Adjusts in 1-unit steps, from 1 to 80 units per setting. Cartridge capacity: 3 mL. Delivery accuracy is not independently validated here.
*For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Titration: Begin at 250 mcg and increase by 250 mcg every 5–7 days as tolerated. Nausea and flushing are common initially and typically subside with continued use.
Reconstitution Steps (Both Peptides)
- Draw 2.4 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct impact on the powder.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date, peptide name, and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use reconstituted solution within approximately 1 week for optimal stability.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan supplies from the exact schedule and total amount separately for each peptide. Changing dilution does not change the mass in a vial.
- Vials: Each labelled vial contains 10 mg. Divide the planned total for that peptide by 10 mg and round up for a theoretical minimum. Discard limits and handling losses may require more.
- BAC: 2.4 mL per vial. Multiply that volume by the required vial count; opened-bottle discard limits and wastage may require additional supplies.
- Measurement devices: 1 mL U-100 syringes or the specified V1 pen, with appropriate sterile single-use needles and a sharps container. Pen priming and residual-volume losses are not included.
Protocol Overview
Summary of both peptide regimens.
- PT-141: On-demand subcutaneous use for sexual function; typical dose 1.75 mg (1750 mcg) administered ≥45 min before activity.
- Melanotan II: Daily subcutaneous injections during loading phase (4–8 weeks), then 2–3× weekly maintenance for pigmentation and related effects.
- Reconstitution: 2.4 mL per separate 10 mg vial; nominal 4.1667 mg/mL for each peptide.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Dosing Protocol
Key differences between the two peptides.
- PT-141: Start at 500–750 mcg; titrate to 1750 mcg as tolerated. On-demand use only; max 8 doses/month.
- Melanotan II: Start at 250 mcg daily; increase by 250 mcg every 5–7 days to target 1000 mcg. Transition to maintenance after desired effect.
- Timing: PT-141 at least 45 min before activity; Melanotan II at any consistent time daily.
- Sites: Rotate injection sites (abdomen, thighs) for both.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; PT-141 shows short-term room-temperature stability (~3 weeks) if needed.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 1 week for optimal potency.
- Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document each dose, time, and injection site to maintain consistency.
- PT-141: Do not exceed 8 doses per month or 1 dose per 24 hours.
- Melanotan II: UV exposure (sun or controlled tanning) during use may enhance pigmentation effects; appropriate sun protection is advised.
How This Works
PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system. PT-141 (bremelanotide) is a metabolite of Melanotan II and was developed specifically for its effects on sexual function without significant pigmentation activity. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Melanotan II retains both melanogenic and sexual-function properties, stimulating melanin production in skin cells (melanocytes) while also activating central pathways involved in sexual arousal.
Potential Benefits & Side Effects
Observations from clinical and research literature.
PT-141
- Shown to increase sexual desire and reduce distress associated with low libido in clinical trials.
- Common side effects include nausea (especially with first doses), flushing, headache, and injection-site reactions.
- May cause transient increases in blood pressure; use with caution in those with cardiovascular conditions.
Melanotan II
- Studied for inducing skin pigmentation (tanning) without UV exposure and for effects on erectile function.
- Common side effects include nausea, facial flushing, fatigue, and appetite suppression, particularly during initial dosing.
- May cause darkening of existing moles or nevi; monitoring is advised.
Lifestyle Factors
Complementary strategies for best outcomes.
- Maintain adequate hydration, especially given potential nausea with initial doses.
- For Melanotan II users seeking pigmentation: controlled, gradual UV exposure may enhance results; always use appropriate sun protection to minimize skin damage risk.
- Prioritize sleep and stress management; both influence hormonal balance and overall response.
- Monitor for any new or changing skin lesions and consult a healthcare provider if noted.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper with an alcohol swab; allow to dry completely.
- Clean the injection site (abdomen or thigh) with an alcohol swab for at least 30 seconds; allow to dry.
- Pinch a fold of skin; insert the needle at 45–90° depending on subcutaneous tissue depth.
- Aspiration is not required for subcutaneous injections; inject slowly and steadily.
- Release the skin fold, withdraw the needle, and apply gentle pressure if needed.
- Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy or irritation.
Recommended Source
Product reference: PT-141 10 mg and Melanotan II 10 mg, supplied in separate vials.
Why Amino Labs?
- High-purity (≥99% HPLC), third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.